Drug intelligence / Profile preview

SFT-001

Development stage: Preclinical
Lead developer: invoX Pharma
Modality: Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

SFT-001 is an inhaled pharmaceutical candidate developed by invoX Pharma for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The drug is delivered using the proprietary Softhaler® technology, a dry powder inhaler (DPI) designed to optimize the delivery of medications to the lungs. SFT-001 is currently in the early stages of development, and while it is part of a broader respiratory pipeline utilizing the Softhaler platform, its specific active ingredient and molecular target have not been publicly disclosed.

Other names: SFT-001-IVOXSFT001-IVOXSFT 001-IVOX

Beyond the preview

Go deeper on SFT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFT-001.

Explore the full profile